Soluble B7-H1: Differences in production between dendritic cells and T cells
- 25 November 2011
- journal article
- other
- Published by Elsevier BV in Immunology Letters
- Vol. 142 (1-2), 78-82
- https://doi.org/10.1016/j.imlet.2011.11.001
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Serum-Soluble B7x Is Elevated in Renal Cell Carcinoma Patients and Is Associated with Advanced StageCancer Research, 2008
- B7-H1 is a ubiquitous antiapoptotic receptor on cancer cellsBlood, 2008
- Questionable Relevance of γδ T Lymphocytes in Renal Cell CarcinomaThe Journal of Immunology, 2008
- Soluble CD276 (B7‐H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serumImmunology, 2008
- B7-H3 Ligand Expression by Prostate Cancer: A Novel Marker of Prognosis and Potential Target for TherapyCancer Research, 2007
- Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancerGynecologic Oncology, 2007
- The New B7s: Playing a Pivotal Role in Tumor ImmunityJournal of Immunotherapy, 2007
- Costimulation, Coinhibition and CancerCurrent Cancer Drug Targets, 2007
- B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survivalProceedings of the National Academy of Sciences of the United States of America, 2006
- B7-H4 Is a Novel Membrane-Bound Protein and a Candidate Serum and Tissue Biomarker for Ovarian CancerCancer Research, 2006